A single infusion of an experimental CRISPR/Cas9 genome editing therapy reduced triglyceride levels by an average of 63 percent in people with severely elevated blood fats.
The in vivo therapy, CTX310, targets the ANGPTL3 gene in the liver, which helps regulate the body's processing of fats. An earlier Phase 1a clinical trial involving 15 people with different lipid disorders found that the therapy could reduce triglyceride and low-density lipoprotein cholesterol levels, both of which are associated with an increased risk of atherosclerotic cardiovascular disease (see BioNews 1355, 1315 and 1288). Now, a Phase 1b clinical trial involving ten people with severe hypertriglyceridaemia has found that, 30 days after receiving the therapy, participants had an average 65 percent reduction in circulating ANGPTL3 protein, alongside a 63 percent reduction in triglycerides.
'This first-in-human study of CRISPR/Cas9 genome editing for severe hypertriglyceridemia found that a single dose of the studied therapy, CTX310, was well tolerated and showed the desired effect on triglyceride levels,' said lead investigator Dr Ashish Sarraju, a cardiologist at Cleveland Clinic, who presented the findings at the American Heart Association Scientific Sessions 2026.
Severe hypertriglyceridaemia is associated with very high levels of blood fats and is known to increase the risk of pancreatitis and cardiovascular disease. People with naturally occurring loss-of-function mutations in the ANGPTL3 gene tend to have lower levels of blood fats and a reduced risk of cardiovascular disease. This makes ANGPTL3 a potential target for treatments aimed at lowering lipid levels. CTX310, developed by CRISPR Therapeutics, uses lipid nanoparticles targeted to liver cells to suppress the ANGPTL3 gene.
All ten participants had severely elevated fasting triglyceride levels. After 30 days, levels had fallen by an average of 63 percent, with reductions ranging from 28 to 85 percent. The treatment also reduced other blood lipid markers, with non-high-density lipoprotein cholesterol falling by an average of 51 percent and apolipoprotein B levels decreasing by 23 percent.
The treatment was generally well tolerated, with no serious adverse events reported. One participant had an infusion-related reaction, which resolved and treatment was completed. Seven participants were followed for at least 90 days, during which reductions in triglycerides and ANGPTL3 were maintained. No cases of acute pancreatitis were reported during the study, however, the investigators acknowledge the small number of participants and short follow-up.
'These are preliminary data in a small population, but the reassuring safety profile and the general efficacy data support the continued study of CTX310 for severe hypertriglyceridemia in larger trials to explore this new frontier for the treatment of this condition,' said Dr Sarraju.
The Phase 1b trial is ongoing, with further patient groups being investigated to establish the treatment's long-term safety, effectiveness and potential as an alternative to lifelong lipid-lowering medication.
Another approach to targeting ANGPTL3 is being developed by Verve Therapeutics. Publishing their preclinical results in Nature, VERVE-201 uses base editing, rather than CRISPR/Cas9, to inactivate the same gene in liver cells.
Sources and References
-
CRISPR Therapeutics presents Phase 1b data for CTX310 demonstrating reductions in ANGPTL3 and triglycerides in patients with severe hypertriglyceridemia at the American Heart Association Scientific Sessions 2026
-
CRISPR/Cas9 gene editing therapy safely slashes severely elevated triglycerides in early trial
-
Gene editing therapy trial dramatically lowers dangerous blood fat levels
-
One CRISPR infusion cut triglycerides 63 percent in ten adults with diabetes and severe levels in small early trial
-
Two gene editors take different paths to silence the same lipid gene

